Drugs / MOTS-c
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07505745 | Feb 2026 → Feb 2027 expected | obesity disorder, prediabetes syndrome | Hudson Biotech | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MOTS-c | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07505745 ↗ |
| Route | Subcutaneous | “Route Subcutaneous injection” NCT07505745 ↗ |